Indaptus Therapeutics Inc - Asset Resilience Ratio
Indaptus Therapeutics Inc (INDP) has an Asset Resilience Ratio of 0.00% as of December 2023. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Check INDP strategic asset allocation to assess the company's strategic physical and investment asset allocation.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2010–2023)
This chart shows how Indaptus Therapeutics Inc's Asset Resilience Ratio has changed over time. See INDP net asset quality index to measure how much of total assets are equity-financed.
Liquid Assets Composition Over Time
This chart breaks down Indaptus Therapeutics Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see INDP company net worth.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $0.00 | 0% |
| Total Liquid Assets | $0.00 | 0.00% |
Asset Resilience Insights
- Limited Liquidity: Indaptus Therapeutics Inc maintains only 0.00% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company maintains a balanced mix of cash and short-term investments.
Indaptus Therapeutics Inc Industry Peers by Asset Resilience Ratio
Compare Indaptus Therapeutics Inc's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN |
Biotechnology | 0.00% |
|
Cyclacel Pharmaceuticals Inc
NASDAQ:CYCC |
Biotechnology | -55.36% |
|
Krystal Biotech Inc
NASDAQ:KRYS |
Biotechnology | 23.06% |
|
Verona Pharma PLC ADR
NASDAQ:VRNA |
Biotechnology | 0.00% |
|
Centessa Pharmaceuticals PLC ADR
NASDAQ:CNTA |
Biotechnology | 33.37% |
|
Beijing Tiantan Biological Products Corp Ltd
SHG:600161 |
Biotechnology | 8.08% |
|
Hebei Changshan Biochem Pharma
SHE:300255 |
Biotechnology | -0.03% |
|
BB Biotech AG
SW:BION |
Biotechnology | 0.05% |
Annual Asset Resilience Ratio for Indaptus Therapeutics Inc (2010–2023)
The table below shows the annual Asset Resilience Ratio data for Indaptus Therapeutics Inc.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2023-12-31 | 0.00% | $0.00 | $14.92 Million | -- |
| 2022-12-31 | 59.88% | $16.81 Million | $28.06 Million | -- |
| 2021-12-31 | 0.00% | $0.00 | $40.58 Million | -- |
| 2019-12-31 | 3.62% | $770.00K | $21.28 Million | +1.45pp |
| 2018-12-31 | 2.17% | $1.33 Million | $61.51 Million | -0.66pp |
| 2017-12-31 | 2.83% | $1.82 Million | $64.55 Million | -4.66pp |
| 2016-12-31 | 7.49% | $1.85 Million | $24.72 Million | -11.40pp |
| 2015-12-31 | 18.90% | $7.04 Million | $37.28 Million | +2.81pp |
| 2014-12-31 | 16.08% | $2.01 Million | $12.49 Million | -21.59pp |
| 2013-12-31 | 37.67% | $5.15 Million | $13.68 Million | -1.86pp |
| 2012-12-31 | 39.53% | $3.07 Million | $7.77 Million | +22.72pp |
| 2011-12-31 | 16.81% | $1.52 Million | $9.06 Million | -23.81pp |
| 2010-12-31 | 40.62% | $5.09 Million | $12.54 Million | -- |
About Indaptus Therapeutics Inc
Indaptus Therapeutics, Inc., a clinical biotechnology company, engages in the development of various anti-cancer and anti-viral immunotherapy products. Its lead clinical candidate consists of Decoy20, which is used to produce single agent activity and/or combination therapy-based durable responses of lymphoma, hepatocellular, colorectal, and pancreatic tumors, and chronic hepatitis B virus, and h… Read more